TGTX - Hold TG Therapeutics For Intriguing Outcomes
2024-06-12 04:40:57 ET
Summary
- TG Therapeutics is a small biotech company that sell ublituximab (a new anti-CD20 monoclonal antibody) for the treatment of multiple sclerosis (MS).
- Anti-CD20 class is the largest ($9bn) and only growing drug class in MS. Ublituximab is a third-in-class drug that has some competitive edge and may reach over $1bn peak sales.
- TG Therapeutics trade at the low level of the fundamental value range (ublituximab NPV is $2-5bn). The near-term stock price primarily depends on sales performance.
- Ublituximab (TG Therapeutics) is likely to become an acquisition target.
- M&A value may be well above x2 to the current price that depends on several factors, which will play out in the next 9-12 months.
Editor's note: Seeking Alpha is proud to welcome Grigorii Borisenko as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more »